Drugs / C225-ILs-dox
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03603379 | Nov 2018 → Nov 2020 | glioblastoma | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
| Phase 1 | NCT01702129 | Jan 2007 → Mar 2010 | cancer | University Hospital, Basel, Switzerland | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C225-ILs-dox | “The therapeutic compound tested in the trial is C225-ILs-dox, a doxorubicin-loaded anti-EGFR-immunoliposome.” NCT01702129 ↗ |
| Known as | anti-EGFR ILs-dox | “We aimed to assess the tolerability and effectiveness of anti-EGFR immunoliposomes loaded with doxorubicin (anti-EGFR ILs-dox) in glioblastoma multiforme patients.” PMID 34998092 ↗ Jan 2022 |
| Modality | Other / unclassified | “EGFR-targeted immunoliposomes to deliver cargo to brain tumor tissue” PMID 34998092 ↗ Jan 2022 |
| Route | Intravenous | “We intravenously infused the nanoparticle at escalating doses” PMID 23153506 ↗ Nov 2012 |
| Target | EGFR | “an investigative nanoparticle targeted against EGFR-overexpressing tumor cells” NCT01702129 ↗ |